title: Anti-idiotype and immunosuppressant treatment of murine lupus.
abstract: The effect of the administration of a xenogeneic anti-idiotype antibody (anti-Id33) to a cross-reactive idiotype (Id33) present on anti-dsDNA antibody was examined in 6-week-old (NZB/NZW) F1 (BWF1) female mice. The administration of anti-Id33 led to a transient reduction in immunoglobulins expressing Id33, followed by a rise at 30 and 34 weeks that was significantly higher than in untreated mice (P less than 0.05). Likewise, anti-dsDNA antibody levels were significantly higher at 10 and 18 weeks than in untreated mice (P less than 0.01). No differences were seen in survival to 40 weeks, proteinuria or the severity of glomerulonephritis. Concurrent administration of cyclosporin A (CyA) with anti-Id33 markedly ameliorated glomerular injury and proteinuria and improved survival. By contrast, glomerular injury, proteinuria and survival were worse in mice treated with cyclophosphamide plus anti-Id33, compared with untreated mice. Neither CyA nor cyclophosphamide treatment, when given with anti-Id33 altered serum levels of anti-dsDNA, anti-ssDNA or Id33+ immunoglobin, compared with untreated mice. The different effects of CyA and cyclophosphamide on T lymphocytes and their discrepant effects on glomerular injury when given with anti-Id33 in this model lead us to postulate a role for T lymphocytes in the glomerular injury of BWF1 lupus.
authors.affiliation: Renal Research Laboratory, Queen Elizabeth Hospital, Edgbaston, Birmingham, England, UK.
authors.forename: C
authors.initials: C
authors.lastname: Morland
authors.forename: J
authors.initials: J
authors.lastname: Michael
authors.forename: D
authors.initials: D
authors.lastname: Adu
authors.forename: T
authors.initials: T
authors.lastname: Kizaki
authors.forename: A J
authors.initials: AJ
authors.lastname: Howie
authors.forename: A
authors.initials: A
authors.lastname: Morgan
authors.forename: N A
authors.initials: NA
authors.lastname: Staines
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology / Q000627:therapeutic use*; D000974:Antibodies, Antinuclear / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003524:Cyclosporins / Q000627:therapeutic use; D004247:DNA / Q000276:immunology; D004277:DNA, Single-Stranded / Q000276:immunology; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005921:Glomerulonephritis / Q000473:pathology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008177:Lupus Vulgaris / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D051379:Mice; D011507:Proteinuria / Q000473:pathology; D012756:Sheep; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D004277:DNA, Single-Stranded; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D004247:DNA